John Sourbeer
Stock Analyst at UBS
(0.69)
# 4,091
Out of 5,139 analysts
44
Total ratings
33.33%
Success rate
-20.51%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $11 → $13 | $8.67 | +44.18% | 7 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $110 → $120 | $120.00 | - | 6 | Oct 31, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $243.83 | +45.59% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $46 → $48 | $48.32 | -1.45% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $98.41 | +143.88% | 2 | Jul 25, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $16.30 | +44.17% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $23.61 | +90.60% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.68 | +19.05% | 3 | Nov 11, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $446.44 | +7.52% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $38.76 | +163.16% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $19.19 | +160.55% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $112.19 | +14.09% | 2 | Jul 27, 2022 |
Cryoport
Nov 5, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $8.67
Upside: +44.18%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $110 → $120
Current: $120.00
Upside: -
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $243.83
Upside: +45.59%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $46 → $48
Current: $48.32
Upside: -1.45%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $98.41
Upside: +143.88%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $16.30
Upside: +44.17%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $23.61
Upside: +90.60%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.68
Upside: +19.05%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $446.44
Upside: +7.52%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $38.76
Upside: +163.16%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $19.19
Upside: +160.55%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $112.19
Upside: +14.09%